The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients

Journal of Cardiovascular Pharmacology

Volumn 17, Issue 1, 1991, Pages 8-12

  Guntzel P ^a   Kobrin, I ^a   Pasquier, C ^a   Zimlichman, R ^b   Viskoper, J R ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Barzilai Hospital   (Israel)

Author keywords

Cilazapril; Converting enzyme inhibitors; Duration of action; Hypertension; Trough blood pressure measurements

Indexed keywords

CILAZAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CILAZAPRIL; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; PYRIDAZINES; TIME FACTORS;

EID: 0026028730     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199101000-00002     Document Type: Article

References (9)

1. Al-Khawaja IM, Carwana MP, Prince H, Whittington J, Raftery EB. Once- and twice-daily bevantolol for systemic hypertension using 24-hour ambulatory intraarterial blood pressure recording. Am J Cardiol 1986;58:17E-20E.
2. Vaisse B, de Gaudemaris R, Asmar R, Poggi L, Mallion JM, Safar M. Non-invasive ambulatory blood pressure measurement over 24 hours: effects of labetalol on the rise of blood pressure in the early morning. Ann Cardiol Angeiol (Paris) 1988;37:621-6.
3. Morgan TO, Nowson C, Murphy J, Snowden R. Compliance and the elderly hypertensive. Drugs 1986;31:174-83.
4. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151-5.
5. Attwood MR, Francis RJ, Hassall CH, et al. New potent inhibitors of angiotensin converting enzyme. FEBS Lett 1984;165:201-6.
6. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol 1987;9:32-8.
7. Thulin T, Andersson G, Scherstén B. Measurement of blood pressure-a routine in need of standardization. Postgrad Med 1975;51:390-5.
8. Antihypertensive drug trough blood level should be between 1/2 and 2/3 of peak level, draft guidelines state: three efficacy trials recommended. FDC Reports. Prescription and OTC Pharmaceuticals 1988;50:9-10.
9. Kögler P. Cilazapril: a new non-thiol-containing angiotensinconverting enzyme inhibitor. Am J Med 1989;87(suppl 6B):50S-5S.